RegulatoryApr 7, 2026, 08:01 AM
Artelo Biosciences Regains Compliance with Nasdaq Listing Rules
AI Summary
Artelo Biosciences received notification from Nasdaq confirming it has regained compliance with the minimum stockholders' equity requirement ($2.5 million) and the annual meeting requirement. The company will be subject to a mandatory panel monitor through April 6, 2027, and faces potential delisting if it falls out of compliance with the equity rule again during that period.
Key Highlights
- Artelo Biosciences regained compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders' equity) and Nasdaq Listing Rule 5620(a) (annual meeting).
- The company is subject to a Mandatory Panel Monitor through April 6, 2027.
- Failure to maintain compliance with the equity rule during the monitoring period could lead to delisting.
Price Impact
More from ARTL